According to the Mayo Clinic website, this disorder can lead to minor or severe bruising and minor or heavy bleeding, and bleeding usually results from low levels of platelets, the cells that help blood clot.Children may develop ITP after a viral infection and usually recover completely without treatment. As for adults, the disorder lasts for a long time.
The British newspaper reported that 350 Britons were affected by this rare disorder after they received the AstraZeneca vaccine, which was developed by Oxford University.
But experts from the University of Edinburgh, who discovered the link between the disorder and the AstraZeneca vaccine, and the number of those whose condition deteriorated to developing blood clots, were satisfied with saying that it is one of the possible complications of this disorder.The researchers based on analyzing the data of 5.4 million people in Scotland between the months of last December and April, about 1.7 million of whom received the first dose of the AstraZeneca vaccine, while 800,000 received the Pfizer vaccine.
The researchers focused on examining the records of the vaccinated, to detect any problems related to the rare disorder, coagulation disorders or bleeding to compare them with those who were not vaccinated.
The researchers did not find any link between Fayez’s vaccine and this disorder, considering that the vaccine is reassuring, but the situation was not the case for the AstraZeneca vaccine, as the risk of developing the rare disorder persisted for 4 weeks after vaccination.
However, the researchers say that there is no evidence that the British vaccine caused blood clots, despite the growing suspicion in this context, stressing that the matter is under investigation.
They added that the benefits of the vaccine outweigh the risks for the vast majority of adults.
The study’s author, Aziz Sheikh, said that the risk of developing this disorder and other conditions of clotting and bleeding should not obscure the great benefits of the AstraZeneca vaccine.
Will Lister, a consultant hematologist at Birmingham University Hospitals, who was not involved in the study, said that the disorder can often be controlled, and the risk of death from it is very rare.
The AstraZeneca vaccine had previously faced the problem of a possible link between it and blood clots.
The European Medicines Agency stated that the risk of death from the Corona virus is much greater than the risk of death due to these rare side effects.
It is noteworthy that several countries around the world resumed giving the vaccine after a brief pause.